ライフサイエンスコーパス: tetanus toxoid

1 immunisation coverage of pregnant women with tetanus toxoid.

2 SCs to recall antigens, Candida albicans and Tetanus toxoid.

3 eration, but not of responses resulting from tetanus toxoid.

4 red with other HIV antigens (such as p24) or tetanus toxoid.

5 in the lymphocyte proliferative response to tetanus toxoid.

6 blocked Ag-specific T cell proliferation to tetanus toxoid.

7 oth at the time of primary immunization with tetanus toxoid.

8 o influence on the proliferative response to tetanus toxoid.

9 ith purified type VI and VIII CPS coupled to tetanus toxoid.

10 ay MLR, and a response to soluble recall Ag, tetanus toxoid.

11 avidly to protein A and weakly to ssDNA and tetanus toxoid.

12 inhibit the primary immunization of mice to tetanus toxoid.

13 4+ cell lines propagated by stimulation with tetanus toxoid.

14 d adults were given a 0.5-ml booster dose of tetanus toxoid.

15 controls responded similarly to mitogens and tetanus toxoid.

16 ecific response by in vivo immunization with tetanus toxoid.

17 ence in the increases in antibody binding to tetanus toxoid.

18 en because MSCs did not affect challenges to tetanus toxoid.

19 kin-13 (0.52, 0.34-0.82, 0.0005) response to tetanus toxoid.

20 d invariably showed the greatest response to tetanus toxoid.

21 tussis vaccines combined with diphtheria and tetanus toxoids.

22 At 12 wk, tetanus toxoid (0.5 mL intramuscular) and Pneumovax II v

23 47 elicited serum IgG2a and mucosal IgA anti-tetanus toxoid Ab responses.

24 (PRP) after 1, 2, or 3 doses of a diphtheria-tetanus toxoids-acellular pertussis (DTaP) vaccine combi

25 polysaccharide (MCC) and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenz

26 ks) infants to receive 3 doses of diphtheria-tetanus toxoids-acellular pertussis-hepatitis B virus-in

27 has been included in the combined diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovir

28 tion with type III polysaccharide coupled to tetanus toxoid administered with an aluminum adjuvant.

29 ontrol mice at the time of immunization with tetanus toxoid adsorbed to aluminum hydroxide (TT/Alum).

30 LR using naive CD4(+) T cells, and inhibited tetanus toxoid Ag presentation by DCs.

31 into the ON/E but not the OB, whereas (125)I-tetanus toxoid alone did not penetrate into the CNS.

32 ast Sweden cohort, were stimulated with Ags (tetanus toxoid and beta-lactoglobulin) and diabetes-rela

33 on index [SI]) as well as to present soluble tetanus toxoid and candida albicans (10- to 100-fold inc

34 al proteins NS3 and NS5, and recall antigens tetanus toxoid and Candida.

35 ic cells that had matured in the presence of tetanus toxoid and CD4+ T cells before and after inducin

36 of the cells forming antibodies against the tetanus toxoid and cholera toxin antigens indicated that

37 ltures and then compared with controls using tetanus toxoid and frozen/thawed third-party cells with

38 ch mAb, MLN-7 (gamma1, kappa), was raised to tetanus toxoid and had no identified cross-reactivity.

39 caques that were immunized sequentially with tetanus toxoid and hepatitis A virus failed to develop a

40 donors to retrieve human antibodies against tetanus toxoid and influenza hemagglutinin (HA) from H1N

41 e significant effect on antibody production, tetanus toxoid and measles IgG levels remained unchanged

42 Hapten 1 was conjugated to tetanus toxoid and mixed with liposomes containing monop

43 phocyte reaction, and normal Ab titers after tetanus toxoid and pneumovax immunization.

44 We studied the memory cells specific for tetanus toxoid and purified protein derivative in 18 hea

45 e capsule, coupled by reductive amination to tetanus toxoid and purified recombinant GBM porin (rPorB

46 XmAb5871 suppressed humoral immunity against tetanus toxoid and reduced serum IgM, IgG, and IgE level

47 investigated in in vitro cocultures by using tetanus toxoid and Salmonella species as antigen models.

48 n demonstrated to maternal immunization with tetanus toxoid and to congenital infections such as rube

49 duration at 24 h and individual responses to tetanus toxoid and Trichophyton mentagrophytes were sign

50 t of a nationally distributed diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine w

51 safety study of a combination diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP),

52 cts received a single dose of diphtheria and tetanus toxoids and acellular pertussis vaccine 10 years

53 estational age and receipt of diphtheria and tetanus toxoids and acellular pertussis vaccine.

54 jugate, human papillomavirus, diphtheria and tetanus toxoids and acellular pertussis, and tetanus and

55 lescent/adult formulations of diphtheria and tetanus toxoids and acellular pertussis, meningococcal c

56 lescent/adult formulations of diphtheria and tetanus toxoids and acellular pertussis, pneumococcal co

57 %) had received >/=3 doses of diphtheria and tetanus toxoids and aP vaccine at the time of their firs

58 completion, which included 4 diphtheria and tetanus toxoids and pertussis, 3 poliovirus, and 1 measl

59 es-mumps-rubella; poliovirus; diphtheria and tetanus toxoids and pertussis; Haemophilus influenzae ty

60 a and a decreased response to diphtheria and tetanus toxoids and to meningococcal, salmonella, and Ha

61 The administration of the diphtheria and tetanus toxoids and whole-cell pertussis (DTP) vaccine a

62 s against these antigens, a control antigen (tetanus toxoid), and phytohemaglutinin were determined i

63 eonatal immunization with diphtheria toxoid, tetanus toxoid, and acellular pertussis vaccine has been

64 Currently inactivated influenza, tetanus toxoid, and acellular pertussis vaccines are rec

65 DNA), anti-extractable nuclear antigen, anti-tetanus toxoid, and antibodies to pneumococcal capsular

66 xoid cross-reactive material (CRM) 197 (DT), tetanus toxoid, and BSA, and combined with an adjuvant,

67 Proliferative responses to PHA, anti-CD3, tetanus toxoid, and dengue Ags were decreased significan

68 y or intranasally with GAS CHO conjugated to tetanus toxoid, and mortality and oral colonization were

69 ponses in vitro to phytohemagglutinin (PHA), tetanus toxoid, and normal donor lymphocytes.

70 irus type 1 (HIV-1) envelope (Env) peptides, tetanus toxoid, and phytohemagglutinin was measured in p

71 mphocyte proliferative responses to Candida, tetanus toxoid, and streptokinase antigens was studied i

72 e prepared by coupling S. suis type 2 CPS to tetanus toxoid, and the immunological features of the po

73 Undervaccination for the diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine.

74 We also determined levels of anti-tetanus toxoid (anti-TT) as a non-oral antigen control.

75 In normal rhesus monkeys immunized with tetanus toxoid, anti-CD20 treatment and resulting deplet

76 ith tetanus fragment C and CT developed anti-tetanus toxoid antibodies and were protected against sys

77 Anti-tetanus toxoid antibody IgG geometric mean concentration

78 Both groups had significant increases in tetanus toxoid antibody levels after vaccination but wit

79 e hypersensitivity, CD4 and CD8 counts, anti-tetanus toxoid antibody levels, erythrocyte complement r

80 affect preexisting antipneumococcal or anti-tetanus toxoid antibody levels.

81 i-PRP (from 5.25 to 2.68 microg/mL) and anti-tetanus toxoid antibody responses (from 0.13 to 0.09 Eq/

82 that CD34(+)/CD86(+) cells can also present tetanus toxoid antigen to memory CD4(+) T cells.

83 rved after the fifth injection of diphtheria-tetanus toxoids-aP (DTaP) vaccine.

84 characterization of memory B cells by using tetanus toxoid as a model antigen.

85 reduced T cell proliferation in response to tetanus toxoid as a recall Ag.

86 the skin, using diphtheria toxoid (DTx) and tetanus toxoid as model antigens.

87 n of the group A polysaccharide and used its tetanus toxoid as the carrier protein to produce the now

88 ningococcal conjugate vaccine that used SIIL tetanus toxoid as the carrier protein.

89 nses to the T cell-dependent protein antigen tetanus toxoid as well as DTH responses were preserved i

90 < 0.01) but an increased immune response to tetanus toxoid, beta-lactoglobulin, and the autoantigens

91 ntrol antigens (glutathionine-S-transferase, tetanus toxoid, Candida albicans, mumps, bovine serum al

92 ation with irradiated anti-RNP (but not anti-tetanus toxoid) CD4(+) cells induced remission of anti-R

93 , B cells and moDCs were pulsed with IgE-NIP-tetanus toxoid complexes and cocultured with autologous

94 ctionally active IgG in response to a dV CPS-tetanus toxoid conjugate (dV-TT), and 98% of neonatal mi

95 his study, Neisseria meningitidis group C PS-tetanus toxoid conjugate (MCPS-TT) vaccine was used to e

96 oci (XenoMouse mice) vaccinated with a PPS-3-tetanus toxoid conjugate and their molecular genetic str

97 e protein A) or a capsular 6B polysaccharide-tetanus toxoid conjugate induced mucosal and systemic an

98 s incorporated into the original beta-mannan tetanus toxoid conjugate providing a tricomponent conjug

99 cine against Candida albicans, a beta-mannan tetanus toxoid conjugate showed poor immunogenicity in m

100 and capsular group C Neisseria meningitidis tetanus toxoid conjugate vaccine (Hib-MenC-TT), administ

101 A serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) wa

102 ly from those obtained with the type III CPS-tetanus toxoid conjugate vaccine and the unconjugated tw

103 V is a single-dose typhoid Vi polysaccharide-tetanus toxoid conjugate vaccine for persons >/=6 months

104 wledge gap, we assessed the efficacy of a Vi-tetanus toxoid conjugate vaccine using an established hu

105 sera from women receiving a GBS type III PS-tetanus toxoid conjugate vaccine, and sera from nonimmun

106 ia meningitidis group A (NmA) polysaccharide-tetanus toxoid conjugate vaccine, PsA-TT (MenAfriVac), d

107 antibody (MAb) prepared against a N-Pr MBPS-tetanus toxoid conjugate vaccine.

108 A monovalent MenA polysaccharide-tetanus toxoid conjugate was therefore developed.

109 jugated to the carrier proteins CRM(197) and tetanus toxoid did not engage TLR2 on HEK or dendritic c

110 individuals with the common recall antigen, tetanus toxoid, disrupts this steady state, resulting in

111 Mice were injected subcutaneously with dLOS-tetanus toxoid (dLOS-TT), dLOS-high-molecular-weight pro

112 intramuscular injections of dLOS-conjugated tetanus toxoid, dLOS-conjugated high-molecular-weight pr

113 C-PS, a TI Ag, or a conjugate of MenC-PS and tetanus toxoid elicited an augmented PS-specific IgG res

114 ombinant Salmonella expressing fragment C of tetanus toxoid elicited dominant Ag-specific Th1-type re

115 nistration of QS-21 with the vaccine protein tetanus toxoid elicited strong serum IgM and IgG Ab resp

116 e other hybrid when used in conjunction with tetanus toxoid for intranasal immunization of BALB/c mic

117 T cell lines specific for B. burgdorferi and tetanus toxoid from subjects with chronic B. burgdorferi

118 pathogen group B streptococci conjugated to tetanus toxoid (GBSIII-TT) as our model vaccine.

119 r polysaccharide vaccine glucuronoxylomannan-tetanus toxoid (GXM-TT) have been shown to be biological

120 (GXM) from individuals immunized with a GXM-tetanus toxoid (GXM-TT) vaccine.

121 Pre-existing immunity to tetanus toxoid had no effect on the induction of AH1-spe

122 re smaller, proliferated well in response to tetanus toxoid, had longer telomeres, and expressed gene

123 e larger, proliferated poorly in response to tetanus toxoid, had shorter telomeres, and expressed gen

124 tussis vaccines combined with diphtheria and tetanus toxoids have proven to be well tolerated, immuno

125 fection or immunizations to influenza virus, tetanus toxoid, hepatitis B Ag, and human papillomavirus

126 zation of healthy adults with GBS type Ia PS-tetanus toxoid (Ia-TT) or Ib-TT glycoconjugate vaccines

127 iencies and stunting, but many had titers of tetanus toxoid IgG antibodies below the protective conce

128 and M (IgM)], hepatitis A virus, rotavirus, tetanus toxoid (IgG), and a panel of recombinant malaria

129 Measles and tetanus toxoid IgGs were measured quantitatively by usin

130 Adsorption of GBS type III CPS-tetanus toxoid (III-TT) conjugate vaccine to alum did no

131 Streptococcus (GBS) type III polysaccharide-tetanus toxoid (III-TT) conjugate.

132 Measles and tetanus toxoid immunisation were not affected.

133 ells, peripheral plasmablasts isolated after tetanus toxoid immunization and memory B cells isolated

134 ent conjugate of (poly)glycerolphosphate and tetanus toxoid in alum plus CpG-oligodeoxynucleotides pr

135 galovirus, varicella-zoster virus (VZV), and tetanus toxoid in normal controls, long-term nonprogress

136 s of AMA and responses to a control antigen, tetanus toxoid, in supernatants.

137 -2 for at least 60 weeks were immunized with tetanus toxoid, inactivated glycoprotein 120-depleted HI

138 etyl PSA Ags were prepared and conjugated to tetanus toxoid, including completely de-N-acetylated PSA

139 from complete ISCOMs (i.e., with an antigen (tetanus toxoid) incorporated) can be modeled as a polydi

140 Tetanus toxoid-induced human PBMC IL-5 and IL-13 secreti

141 ion of monocyte-derived dendritic cells, and tetanus toxoid-induced PBMC proliferation were assessed

142 Surprisingly, in the ISCOMs, the tetanus toxoid is located just below the membrane inside

143 Escherichia coli K92 capsular polysaccharide-tetanus toxoid (K92-TT) conjugate vaccine are here evalu

144 Stimulation with tetanus toxoid led to an increased proportion of CD45RA+

145 ia meningitidis group C (MCPS) conjugated to tetanus toxoid (MCPS-TT) and the same response in BALB/c

146 onjugated to proteins, e.g., MCPS coupled to tetanus toxoid (MCPS-TT), elicits a thymus-dependent (TD

147 tomegalovirus-pp65 (immunodominant protein), tetanus toxoid, measles, mumps, and rubella.

148 The rAls3p-N vaccine, but neither tetanus toxoid nor a related Als protein (Als5p), improv

149 Serum levels of RF, but not those of anti-tetanus toxoid or anti-pneumococcal polysaccharide antib

150 jugated to proteins, e.g., MCPS coupled with tetanus toxoid or the diphtheria toxin derivative CRM197

151 to recall Ags (purified protein derivative, Tetanus toxoid, or flu/EBV/CMV viral mix) in LN, despite

152 were intranasally immunized with ovalbumin, tetanus toxoid, or influenza virus either alone or toget

153 etic of GXM, P13, to either BSA, P13-BSA, or tetanus toxoid, P13-tetanus toxoid, was examined in BALB

154 systemic reactions observed with diphtheria-tetanus toxoids-pertussis vaccine but has not eliminated

155 dies when immunized orally with a vaccine of tetanus toxoid plus cholera toxin as adjuvant.

156 One-year-old mice given nasal tetanus toxoid plus the chimeric toxin as adjuvant were

157 l polysaccharide of serotype 1 conjugated to tetanus toxoid (Pnc1-TT) as a model vaccine.

158 Tetanus toxoid, pneumococcal polysaccharide, and KLH vac

159 y less than that in animals immunized with a tetanus toxoid-polysaccharide conjugate.

160 ce with a conjugate of PPS of serotype 3 and tetanus toxoid (PPS3-TT) and determined the antibody res

161 ific for epitopes of HCMV phosphoprotein-65, tetanus toxoid precursor, EBV nuclear Ag 2, or HIV gag p

162 responses to recall Ags (influenza virus and tetanus toxoid) presented by Langerhans cells (LC) in si

163 confirm the constructive function of AEP in tetanus toxoid processing, but they are discordant with

164 coccal capsular polysaccharide conjugated to tetanus toxoid produce Abs that can be either protective

165 acetyl-XGKGKGKGCONH2 (where X represents the tetanus toxoid promiscuous T cell epitope (TT) sequence

166 iour and unlike the previously characterised tetanus toxoid protein (slightly extended and hydrodynam

167 th a then-new meningococcal A polysaccharide-tetanus toxoid protein conjugate vaccine (PsA-TT, or Men

168 Conjugation with tetanus toxoid protein however greatly increased the mol

169 indicated that HTL recall responses to whole tetanus toxoid protein were reduced in chronically infec

170 articular, MUC1 glycopeptide conjugates with Tetanus toxoid proved to be efficient vaccines inducing

171 erythrocytes, vaccinia virus, rotavirus, or tetanus toxoid provides evidence for reactivation of ane

172 is (DTaP) combined with Hib-PS conjugated to tetanus toxoid (PRP-T) and hepatitis B (HB) (DTaP-PRP-T-

173 PUB1 conjugated to tetanus toxoid (PUB1-TT) induced a type 8 PS-specific an

174 Tetanus toxoid reactive clones and a purified protein de

175 s generated from controls and in none of the tetanus toxoid-reactive T cell lines generated from eith

176 luster complex, keyhole limpit hemocyanin or tetanus toxoid-reactive Th cells promoted generation of

177 In 2012, Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular

178 fant contact, receive a single dose of Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular

179 Maternal immunization with tetanus toxoid, reduced diphtheria toxoid, and acellular

180 ia Department of Health recommended that the tetanus toxoid, reduced diphtheria toxoid, and acellular

181 les for certain vaccines (eg, meningococcal; tetanus toxoid, reduced diphtheria toxoid, and reduced a

182 d to the minimal domain of the C fragment of tetanus toxoid (referred to herein as Tem1-TT vaccine).

183 Tetanus toxoid resulted in even greater production.

184 Using tetanus toxoid specific and HLA-DR-restricted T lymphocy

185 Testing the distribution of tetanus toxoid-specific (TT(+)) mBCs revealed their pres

186 in MLA derivatives enhance the production of tetanus toxoid-specific antibodies in mice.

187 frag) induced significantly higher levels of tetanus toxoid-specific antibody than BRD509(pKK/C frag)

188 study the phenotype and frequency of D- and tetanus toxoid-specific B cells by culturing B cells in

189 Importantly, tetanus toxoid-specific IFN-gamma production by PBMC fro

190 The concentrations of tetanus toxoid-specific IgG also increased comparably an

191 Consistently, the avidity of tetanus toxoid-specific serum antibodies was substantial

192 RD509(pKK/ppagC/C frag)] mounted the highest tetanus toxoid-specific serum antibody response.

193 ve generated myelin basic protein (MBP)- and tetanus toxoid-specific T cell clones from CD45RA+/RO- a

194 Blockade of CD28 failed to inhibit tetanus toxoid-specific T cell proliferation in both the

195 s associated with significant improvement of tetanus-toxoid-specific T-cell response.

196 ll responses against autoantigen or repeated tetanus toxoid stimulations require both Kv1.3 and KCa3.

197 on of antibodies to a neutral antigen, i.e., tetanus toxoid, the consumption of IgG EndoCab antibody

198 OCs also present soluble protein tetanus toxoid to activate autologous CD4+ T cells.

199 e (IIIPS) or with IIIPS covalently linked to tetanus toxoid to assess specificity, sensitivity, and p

200 ls with CpG ODN also enabled presentation of tetanus toxoid to CD8(+) T cells, resulting in CD8(+) T

201 by reductive amination at multiple sites to tetanus toxoid to create a polysaccharide-protein conjug

202 retained the ability to process and present tetanus toxoid to T cells, which indicates that response

203 been eliminated to provide immunisation with tetanus toxoid to women of childbearing age.

204 Intranasal vaccination with (125)I-tetanus toxoid together with unlabeled CT as adjuvant re

205 Specific antibodies binding to tetanus toxoid (total IgG) and pneumococcal capsular pol

206 universal helper T lymphocyte (HTL) epitope tetanus toxoid (TT) 830-843.

207 igens, we compared the antibody responses to tetanus toxoid (TT) after tetanus vaccination in 193 sub

208 ally or orally to mice orally immunized with tetanus toxoid (TT) and CT to determine whether this cyt

209 ll as the proliferation of HLA-DR-restricted tetanus toxoid (TT) and influenza hemagglutinin-specific

210 ix-week-old C57BL/6 mice were immunized with tetanus toxoid (TT) and treated with RA and/or PIC at pr

211 eningococcal conjugate vaccine, PsA-TT, uses tetanus toxoid (TT) as a carrier protein (PsA-TT).

212 gG and B-cell receptor repertoires following tetanus toxoid (TT) booster vaccination.

213 Finally, the recall response to tetanus toxoid (TT) by PBMC from individuals vaccinated

214 BALB/c mice were nasally immunized with tetanus toxoid (TT) combined with CT, and the responses

215 mmunization of mice with an optimized heroin-tetanus toxoid (TT) conjugate formulated with adjuvants

216 type II or III capsular polysaccharide (CPS)-tetanus toxoid (TT) conjugate vaccines combined in a sin

217 However, tolerant mice immunized with tetanus toxoid (TT) developed high anti-TT antibody, dem

218 volvulus infection on the immune response to tetanus toxoid (TT) following tetanus vaccination was st

219 lines were generated to either MBP, PLP, or tetanus toxoid (TT) from 34 relapsing-remitting MS patie

220 cholera toxin (CT) on the immune response to tetanus toxoid (TT) given by intranasal or oral routes.

221 We assessed the impact of PsA-TT on tetanus toxoid (TT) immunity by quantifying age- and sex

222 sed as mucosal immunogen and as adjuvant for tetanus toxoid (TT) in mice.

223 nt influenza seasonal subunit vaccine and to tetanus toxoid (TT) in mouse.

224 train 26397 was detoxified and conjugated to tetanus toxoid (TT) or a cross-reactive mutant (CRM) of

225 P13 was conjugated to tetanus toxoid (TT) or diphtheria toxoid (DT) and admini

226 s antigen-presenting cells for either intact tetanus toxoid (TT) or for a TT peptide.

227 The detoxified LOS (dLOS) was coupled to tetanus toxoid (TT) or high-molecular-weight proteins (H

228 gens, hPBMC were cultured in the presence of tetanus toxoid (TT) or phytohemagglutinin (PHA) and eith

229 was isolated, detoxified, and conjugated to tetanus toxoid (TT) or the cross-reactive mutant (CRM) o

230 ells and present an exogenous DR1-restricted tetanus toxoid (TT) peptide, indicating that the transdu

231 (+) T cells that proliferated in response to tetanus toxoid (TT) presented by autologous CD B cells.

232 coccal capsular polysaccharide conjugated to tetanus toxoid (TT) produce Abs that, based on the epito

233 oconjugate made by conjugating this with the tetanus toxoid (TT) protein have been characterized and

234 polysaccharides, and very different from the tetanus toxoid (TT) protein used for the conjugation.

235 rhoptry-associated protein-1 [RAP-1]) and to tetanus toxoid (TT) tested using enzyme-linked immunosor

236 osaccharide units (9Glc-NH(2)) conjugated to tetanus toxoid (TT) to induce antibodies in rabbits.

237 ns, individual GBS CPSs have been coupled to tetanus toxoid (TT) to prepare vaccines with enhanced im

238 ion, individual GBS CPS have been coupled to tetanus toxoid (TT) to prepare vaccines with enhanced im

239 In clinical trials, maternal tetanus toxoid (TT) vaccination is effective in protecti

240 eive an intramuscular dose of GBS type V CPS-tetanus toxoid (TT) vaccine (n=15), GBS type V CPS-cross

241 present study, we hypothesized that the anti-tetanus toxoid (TT) vaccine response of neonatal mice co

242 Tetanus toxoid (TT) was encapsulated in microparticles p

243 dLOS-OMP and OS-OMP conjugates, while a dLOS-tetanus toxoid (TT) was synthesized for comparison.

244 MV infection or were recently immunized with tetanus toxoid (TT) were included as controls.

245 he detoxified LPS of S. paratyphi A bound to tetanus toxoid (TT) were prepared by several schemes.

246 dinium tetrafluoroborate (CDAP) and bound to tetanus toxoid (TT) with adipic acid dihydrazide as a li

247 C (ToxC) of tetanus toxin, and (ii) soluble tetanus toxoid (TT) with cholera toxin (CT) as an adjuva

248 IgA1 antibodies against a systemic antigen, tetanus toxoid (TT), and a mucosal antigen, Helicobacter

249 CFSE-labeled PBMCs were stimulated with CMV, tetanus toxoid (TT), and C albicans antigens and subsequ

250 entous hemagglutinin (FHA), pertactin (Prn), tetanus toxoid (TT), and diphtheria toxoid (DT) were mea

251 ve SLE patients immunized with pneumococcal, tetanus toxoid (TT), and Haemophilus influenzae type B (

252 hoproliferative responses to HIV-1 antigens, tetanus toxoid (TT), and mitogens were measured and corr

253 hly purified ganglioside G(D1a), pulsed with tetanus toxoid (TT), and washed, the expected Ag-induced

254 red in the presence of either recall antigen tetanus toxoid (TT), anti-CD3 (OKT3) monoclonal antibody

255 roteins, keyhole limpet hemocyanin (KLH) and tetanus toxoid (TT), as well as an HLA A2.1-restricted i

256 Conjugate vaccines were created by coupling tetanus toxoid (TT), gp120, and/or env2-3 with group B s

257 y normal human mononuclear cells, induced by tetanus toxoid (TT), human thyroglobulin (TG), Escherich

258 encapsulation of two antigens, ovalbumin and tetanus toxoid (TT), in PLGA microspheres was adjusted b

259 D4(+) T cells via a carrier protein, such as tetanus toxoid (TT), resulting in the induction of PS-sp

260 ponded to vaccination with GXM conjugated to tetanus toxoid (TT), the relative magnitude of the antib

261 After vaccination with tetanus toxoid (TT), TT-specific immune responses in hum

262 q for five injections and a foreign antigen, tetanus toxoid (tt), was given at the beginning or the e

263 C meningococcal polysaccharides, as well as tetanus toxoid (TT), was used to investigate the BCR rep

264 ry to activate myelin basic protein (MBP) or tetanus toxoid (TT)-reactive CD4 T cells were compared b

265 gand (rCD40L)-activated non-T cells, whereas tetanus toxoid (TT)-specific clones exhibited only helpe

266 t B. anthracis protective antigen (rPA), and tetanus toxoid (TT).

267 subjects following a booster injection with tetanus toxoid (TT).

268 toxins were coadministered with radiolabeled tetanus toxoid (TT).

269 heir nasal delivery with the protein vaccine tetanus toxoid (TT).

270 estricted influenza matrix peptide (MP), and tetanus toxoid (TT).

271 HIV-1 envelope glycoprotein (CN54gp140) and tetanus toxoid (TT).

272 olysaccharide (GBSIII) to ovalbumin (OVA) or tetanus toxoid (TT).

273 and lack of lymphoproliferative response to tetanus toxoid (TT; 73%) after immunization and impaired

274 d spontaneously respond to a recall antigen (tetanus toxoid [TT] vaccine) or respond to a recall anti

275 unogenicity of combining 2 Hib vaccines (Hib-tetanus toxoid [TT]-A and Hib-TT-B) with diphtheria-TT-a

276 A Th epitope of tetanus toxoid, TT830, and the antagonistic peptide for

277 Immunization of mice with tetanus toxoid-type III polysaccharide conjugate did not

278 rozoite surface protein (MSP-1(19)) fused to tetanus toxoid universal T-cell epitopes P30 and P2.

279 of type V GBS capsular polysaccharide (CPS)-tetanus toxoid (V-TT) conjugate vaccine (CV) were assess

280 who received their first dose of PRP-T after tetanus toxoid vaccination, disease was unlikely from 1

281 Responses to tetanus toxoid vaccine (>or=4-fold rise) were similar in

282 received GBS type Ia capsular polysaccharide-tetanus toxoid vaccine (Ia CPS-TT), Ib CPS-TT, or III CP

283 aluminum phosphate, a commercially available tetanus toxoid vaccine adjuvanted with potassium alum, a

284 erated after immunizations with conventional tetanus toxoid vaccine, and (2) preventing pathological

285 sily prevented by maternal immunisation with tetanus toxoid vaccine, and aseptic obstetric and postna

286 ricomponent vaccine, but not the beta-mannan tetanus toxoid vaccine, showed activation of BMDCs.

287 ntation, patients received HIB-conjugate and tetanus toxoid vaccines at 3, 6, 12, and 24 months and 2

288 ur cells in culture, while MUC1 glycopeptide-Tetanus toxoid vaccines elicited antibodies in mice whic

289 mended to replace the booster diphtheria and tetanus toxoid vaccines in adolescents.

290 When used as an adjuvant for tetanus toxoid vaccines, certain MLA derivatives enhance

291 es may be alternatives to GBS polysaccharide-tetanus toxoid vaccines, eliciting additional antibodies

292 th 23-valent pneumococcal polysaccharide and tetanus toxoid vaccines.

293 Antibody immunity to tetanus toxoid was assessed as a control.

294 by the investigational conjugate vaccine GXM-tetanus toxoid was examined.

295 The change in response to tetanus toxoid was significantly different from that of

296 f alpha4beta7 on T cells specific for KLH or tetanus toxoid was studied.

297 either BSA, P13-BSA, or tetanus toxoid, P13-tetanus toxoid, was examined in BALB/c and CBA/n mice th

298 plasmablast reactivity to a control antigen, tetanus toxoid, was minimal and similar in all groups.

299 omain (ICD), HER2-ECD, p53, IGFBP2, CEA, and tetanus toxoid were examined.

300 Pf merozoite surface protein-1 (MSP-1), and tetanus toxoid were measured by indirect enzyme-linked i